Cancer drugs face funding delays: report

A report commission by Medicines Australia’s Oncology Industry Taskforce, comprising 16 pharmaceutical companies, found oncology drugs struggled to receive timely PBS listings.

Presented today to the country’s leading cancer specialists at the Medical Oncology Group Australia (MOGA) Annual Scientific Meeting in Melbourne, the report revealed many stakeholders felt access to oncology drugs was “often suboptimal and unsustainable”.

Associate Professor Gary Richardson, chairman of MOGA which is currently campaigning to have tamoxifen PBS listed for prevention of breast cancer, said costly